

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

4baseCare signs MoU with Maharashtra Govt to establish Centre of Excellence for precision oncology

31 March 2026 | News

Centre will be equipped with Next Generation Sequencing (NGS) technology to enable comprehensive genomic profiling for cancer patients



Bengaluru-based startup 4baseCare has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra to establish a Centre of Excellence for Precision Oncology in the state.

The MoU aims to integrate genomic-driven cancer care into Maharashtra's public health system. As part of the collaboration, 4baseCare will deploy its OncoTwin platform, an artificial intelligence (AI)-based tool that enables oncologists to derive actionable treatment insights by mapping each patient's genomic and clinical profile against large, real-world outcomes datasets. OncoTwin was recently selected for the MSK iHub programme of Memorial Sloan Kettering Cancer Centre, New York, USA.

The MoU signing took place at PULSE 2026, India's leading Healthcare and Medical Education Summit, that was held in Mumbai recently.

Commenting on the MoU, Hitesh Goswami, CEO & Co-Founder, 4baseCare, said, "This MoU marks an important step towards creating more effective and personalized cancer treatment approaches, and we are pleased to see Maharashtra taking the lead in making this easily accessible to a wider population. At 4baseCare, our aim is to integrate genomic insights into routine cancer care, enabling oncologists to make more informed, evidence-based treatment decisions."

The Centre of Excellence will focus on enabling access to precision oncology, building local clinico-genomic datasets, and supporting oncologists across government healthcare institutions in Maharashtra with data-backed treatment insights. The Centre will be equipped with Next Generation Sequencing (NGS) technology to enable comprehensive genomic profiling for cancer patients. This will support Oncologists in making more targeted, personalised treatment decisions based on each patient's genomic profile.